News Hub | News Direct

Former ESPN NBA Insider Adrian Wojnarowski Joins Players Health’s NIL Advisory Board, Begins Brand Ambassadorship

Players Health

Players Health, the leading provider of athlete safety and insurance solutions, today announced the appointment of St. Bonaventure men’s basketball general manager and former ESPN NBA Insider Adrian “Woj” Wojnarowski to its NIL Advisory Board and as a brand ambassador. The partnership formally began on Friday, April 4, when Woj appeared on behalf of Players Health at the NCAA Men’s Final Four in San Antonio, Texas. Widely regarded as one of the most respected names in sports media, Woj joins the Players Health NIL Advisory Board after retiring from his award-winning role at ESPN, where he spent years breaking NBA news and guiding coverage across the network’s platforms. Now, as the general manager for St. Bonaventure men’s basketball, he oversees a broad range of responsibilities, including name, image, and likeness opportunities, transfer portal management, and alumni relations. “St. Bonaventure has given me opportunity to utilize three decades of relationships to create the greatest possible impact on the next generation of athletes,” said Wojnarowski. “Joining Players Health allows me to widen that circle even further, especially now, when NIL has opened remarkable doors. We want to ensure that while these athletes seize their opportunities, they do so with the safety and support they deserve.” Wojnarowski will join fellow industry leaders on the Players Health NIL Board of Advisors to drive strategic initiatives, engage in educational panels, and advance the Players Health mission at industry events. “Woj revolutionized sports journalism with his approach to reporting and relationships, and now he is bringing that same forward-thinking mindset to our team as one of the first GMs in college athletics,” said Tyrre Burks, Founder & CEO of Players Health. “NIL has fundamentally transformed the collegiate landscape, and there is no one better equipped to help us navigate this new era. His insights will be invaluable to our success as we work to develop solutions that keep athletes safe, supported, and empowered at every stage of their athletic career.” Players Health and Wojnarowski traveled to San Antonio for the NCAA Men’s Final Four, where Wojnarowski took part in a panel discussion on the evolution of the general manager role in collegiate athletics. The panel was held on Friday, April 4 at the Boggess Center during the Global NIL Conference hosted by Silver Waves Media. The announcement comes just three months after Players Health closed a $60 million Series C funding round to accelerate the expansion of their innovative athlete safety and insurance solutions across youth, recreational, collegiate, and professional sports. To learn more, visit: https://www.playershealth.com/ Players Health is a sports technology company providing digital risk management services, reporting tools and insurance products to sports organizations to empower them to stay ahead of their ever-changing safety and compliance responsibilities. Working towards establishing the safest environment for athletes, Players Health views the health and safety of athletes as a priority in today's sports landscape. Contact Details Hot Paper Lantern playershealth@hotpaperlantern.com Company Website https://www.playershealth.com

April 09, 2025 09:00 AM Eastern Daylight Time

Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation

OSTX DAWN CADL YMAB

The oncology sector in the U.S. is on the verge of a transformative breakthrough. With the cancer therapeutics market already valued at over $170 billion in 2024 and expected to exceed $500 billion by 2034, the industry is experiencing a surge of innovation driven by cutting-edge treatments like immunotherapies and targeted therapies. As cancer rates continue to rise, particularly among children and underserved populations, the urgency for novel solutions has never been greater. Investors are increasingly drawn to this rapidly evolving field, where new therapies are not just improving survival rates but offering hope where there was none. With breakthroughs happening at an unprecedented pace, the oncology space presents an exciting and compelling opportunity for those looking to invest in the future of healthcare. Now, let’s take a look at a few promising stocks in this expanding sector that could be worth keeping an eye on. OS Therapies (NYSE-A: OSTX) is a clinical-stage biotech company that’s aiming to make a real difference in one of the toughest areas of medicine—osteosarcoma, a rare and aggressive bone cancer that mostly affects children and young adults. Their lead drug, OST-HER2, is not your typical cancer treatment. It's an off-the-shelf immunotherapy that uses a modified form of Listeria bacteria to kickstart the body’s immune system into attacking cancer cells that express the HER2 protein. So far, the results have been very promising. In a Phase 2b clinical trial involving 39 patients with recurrent osteosarcoma that had spread to the lungs but was surgically removed, OST-HER2 showed a statistically significant boost in 12-month event-free survival—33% compared to 20% in similar patients who didn’t receive the treatment (p=0.0158). That’s a big deal in a cancer type where survival rates haven’t improved much in decades. "We believe OST-HER2 will make a significant difference in the treatment of osteosarcoma and welcome the opportunity to engage with FDA to get this investigational treatment to patients as quickly as possible,” said Paul Romness, CEO of OS Therapies. And the company is moving fast. OST-HER2 has already received special FDA and European designations, including: Rare Pediatric Disease Designation (RPDD) Fast Track Designation Orphan Drug Designation in both the U.S. and Europe These help speed up the development and review process. OS Therapies is now preparing to submit a Biologics License Application (BLA) to the FDA by late 2025, with the hope of receiving Accelerated Approval shortly after. In fact, the company recently requested a formal meeting with the FDA to agree on surrogate endpoints—essentially the key data the agency wants to see—in support of Breakthrough Therapy Designation and Accelerated Approval. That meeting is expected to happen in Q2 2025, and if all goes well, OST-HER2 could be approved by year-end. “We are excited to meet with the FDA... The goal is receiving Accelerated Approval for OST-HER2 by year-end 2025,” said Dr. Robert Petit, OS Therapies’ Chief Medical & Scientific Officer. There’s also potential upside beyond approval. If the drug is greenlit before September 30, 2026, OS Therapies is eligible for a Priority Review Voucher (PRV)—a valuable incentive from the FDA that the company could sell. A recent PRV sold for $150 million in February 2025, and that kind of windfall could help OS Therapies fund its next programs without needing to raise more money. OST-HER2 isn’t just being tested in people—it’s also been conditionally approved by the USDA for treating osteosarcoma in dogs, which naturally develop the disease in much the same way as humans. Dogs with cancer have been shown to respond to OST-HER2, and researchers are using this data to better understand which biomarkers might predict a strong response in people. Why does this matter? Because human and canine osteosarcoma share 96% genetic similarity. This growing field of Comparative Oncology is giving scientists like those at OS Therapies a unique window into how these therapies might work even before full human trials are complete. The treatment—and its story—will even be featured in the upcoming PBS documentary “Shelter Me: The Cancer Pioneers.” OST-HER2 is just the beginning. OS Therapies is also developing a next-generation Antibody Drug Conjugate (ADC) platform with tunable payloads—meaning they can design custom treatments for different cancers. This ADC program could offer future partnering or licensing opportunities, helping diversify the company’s pipeline. Financially, OS Therapies appears solid. The company completed both an IPO and private placement in 2024, raising $12 million and projecting enough cash to operate through mid-2026. With the heaviest clinical costs now behind them, OS Therapies expects lower spending moving forward. “We expect a significantly reduced outlay beginning in the second quarter of 2025,” said Chris Acevedo, CFO of OS Therapies. “We have reduced our burn rate substantially... and expect cash on hand to last into 2026.” Investors interested in emerging biotech should keep a close eye on OS Therapies (OSTX). With: Strong Phase 2b results Imminent regulatory milestones High-value PRV opportunity A unique canine-human comparative oncology angle A growing immunotherapy and ADC pipeline OSTX could be on the verge of something big. If OST-HER2 wins approval in late 2025, not only could it bring hope to children and families fighting this devastating disease, but it might also mark a major inflection point for the company’s valuation and visibility in the biotech space. Candel Therapeutics, Inc. (Nasdaq: CADL) is a clinical-stage biopharmaceutical company that focuses on developing off-the-shelf multimodal biological immunotherapies for cancer treatment. The company’s approach includes two distinct immunotherapy platforms: one using genetically modified adenovirus (CAN-2409) and the other using herpes simplex virus (CAN-3110). CAN-2409 is currently being tested in phase 2a clinical trials for non-small cell lung cancer (NSCLC), and it has completed phase 2a and phase 3 trials in pancreatic cancer and localized prostate cancer, respectively. Meanwhile, CAN-3110, from the herpes simplex virus platform, is undergoing a phase 1b clinical trial in recurrent high-grade glioma (rHGG). Candel also employs its enLIGHTEN Discovery Platform to identify new viral immunotherapies for solid tumors. In December 2024, Candel announced positive final survival data from a phase 2a clinical trial involving patients with borderline resectable pancreatic ductal adenocarcinoma (PDAC). Patients treated with CAN-2409 alongside standard care experienced a significant median overall survival benefit of 31.4 months, compared to just 12.5 months in the control group. The data indicated that long-term survivors in the treatment group had a substantially better survival rate, even in metastatic disease, highlighting the sustained benefits of CAN-2409. This promising data led the FDA to grant both fast-track and orphan drug designations for CAN-2409 in pancreatic cancer. The company also revealed positive results from its phase 3 clinical trial of CAN-2409 in prostate cancer in December 2024. In this trial, CAN-2409, combined with standard radiation therapy, resulted in a 30% reduction in the risk of recurrence or death compared to the control group. In addition, the treatment arm demonstrated an 80.4% pathological complete response rate in post-treatment biopsies, compared to 63.6% in the control group. These findings are seen as a significant step toward regulatory approval for CAN-2409 in the treatment of localized prostate cancer, and the study was conducted under a Special Protocol Assessment (SPA) with the FDA. Candel also provided an update on its phase 1b trial of CAN-3110 in recurrent high-grade glioma (rHGG). Data presented at the 6th Annual International Oncolytic Virotherapy Conference in October 2024 showed promising early survival outcomes, with three out of six patients surviving for over a year following repeated doses of CAN-3110. The company received both fast-track and orphan drug designations from the FDA for CAN-3110 in rHGG. Furthermore, Candel entered into a strategic partnership with IDEA Pharma, a biopharmaceutical strategy consultancy, in 2024. This collaboration will provide commercial insights into the development and commercialization of CAN-2409. Additionally, Dr. Elizabeth M. Jaffee, a leading pancreatic cancer expert, joined the company’s Research Advisory Board, enhancing its focus on advancing treatments for pancreatic cancer. In April 2025, Candel published the results of a phase 1b trial exploring the combination of CAN-2409 with nivolumab and standard care in newly diagnosed high-grade glioma patients. The data showed that the combination was well tolerated and resulted in extended survival for a subset of patients. A notable finding was the increase in T cell receptor (TCR) density and diversity, which correlated with improved survival outcomes. This reinforces the potential of CAN-2409 as a treatment for a wide range of solid tumors. Financially, Candel reported research and development expenses of $4.8 million for the fourth quarter of 2024, down from $7.3 million the previous year. General and administrative expenses increased slightly to $3.3 million for the quarter. The company posted a net loss of $14.1 million for the quarter, compared to a net loss of $11.1 million in the same period the previous year. For the full year 2024, Candel’s net loss amounted to $55.2 million, up from $37.9 million in 2023. As of December 31, 2024, the company had $102.7 million in cash and equivalents, which is expected to fund its operations into the first quarter of 2027. Y-mAbs Therapeutics, Inc. (Nasdaq: YMAB) is a biopharmaceutical company that is making significant strides in the fight against pediatric cancer, particularly high-risk neuroblastoma. Neuroblastoma is a rare and aggressive cancer that mainly affects children, and Y-mAbs is dedicated to improving the outcomes for patients who are facing this challenging disease. The company has developed DANYELZA (naxitamab), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. This breakthrough treatment offers hope to children who have exhausted other therapy options. One of the most promising aspects of Y-mAbs is its work with naxitamab, a treatment that has shown strong efficacy in clinical trials. According to a Phase 2 clinical trial published in Nature Communications, naxitamab demonstrated a 50% overall response rate (ORR) among patients with relapsed or refractory high-risk neuroblastoma. Notably, the therapy showed particularly strong results in targeting residual disease in the bone and bone marrow, which are common areas where cancer cells hide and resist traditional chemotherapy. Naxitamab is an anti-GD2 monoclonal antibody, meaning it targets the GD2 molecule found on the surface of neuroblastoma cells. This therapy is combined with granulocyte-macrophage colony-stimulating factor (GM-CSF), a substance that boosts the immune system to fight cancer. In clinical trials, naxitamab has shown manageable safety and promising efficacy, with many patients achieving a partial or complete response. In fact, 58% of patients with bone disease saw a positive response, making it an essential option for those who haven’t responded to other treatments. Y-mAbs has been actively working to expand the reach of DANYELZA globally. In 2024, the company reported significant revenue growth from its international markets, particularly in Europe and Asia. With DANYELZA now available in 69 U.S. centers and expanding into new regions, the company is well-positioned to bring this life-saving treatment to more children in need. As of early 2025, Y-mAbs has adjusted its business strategy to focus on expanding the clinical development of its Radiopharmaceuticals Platform, alongside continuing to drive the growth of DANYELZA. The company has a robust pipeline, including its innovative SADA PRIT technology, which could open up new avenues for treating solid tumors in pediatric cancer patients. Despite a net loss in 2024, Y-mAbs is focusing on cost efficiency and capital investment to fuel future growth. With a strong balance sheet and clear plans to expand its clinical and commercial efforts, Y-mAbs could offer significant upside potential for investors interested in the growing field of pediatric cancer therapeutics. For investors looking to support innovative treatments in pediatric cancer, Y-mAbs Therapeutics presents a unique opportunity, with a solid product, promising clinical data, and an evolving strategy for growth. Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN ) is making significant strides in pediatric cancer treatment, tackling one of the most critical areas of unmet need in the oncology space. The company’s lead drug, OJEMDA (tovorafenib), is a promising targeted therapy designed to treat pediatric low-grade glioma (pLGG), a rare brain tumor that predominantly affects children. OJEMDA is a Type II RAF kinase inhibitor, targeting BRAF mutations that are common in pLGG. Approved by the FDA under accelerated approval, the treatment is a breakthrough in a field where treatment options have been limited. Since its launch in April 2024, OJEMDA has shown strong sales, with net product revenues of $57.2 million for the full year. In the first eight months post-launch, over 1,600 prescriptions were written, highlighting the demand for new therapies in this space. Day One has positioned OJEMDA as a cornerstone of its pipeline, and the company is already advancing its clinical strategy with a global, pivotal Phase 3 trial called FIREFLY-2. Full enrollment in the trial is expected by the first half of 2026, which could pave the way for further regulatory progress. Additionally, OJEMDA received Exclusively Pediatric designation from the Centers for Medicare & Medicaid Services in late 2024, which is expected to reduce the rebate percentage for the drug, further supporting its commercial viability. The company’s financial outlook appears solid, with a year-end 2024 cash balance of $531.7 million, providing a strong runway for future growth. Day One is also making progress in other areas, including its development of DAY301, a targeted antibody-drug conjugate (ADC), which has entered early-stage clinical trials. If successful, DAY301 could add to Day One’s growing pipeline and diversify its offerings in the pediatric oncology market. While Day One recorded a net loss in 2024, the company’s focus on expanding access to OJEMDA and advancing its pipeline positions it well for long-term success. For investors, Day One represents a unique opportunity to support innovation in pediatric cancer therapeutics, with a promising product, a strong pipeline, and a dedicated team pushing the boundaries of what’s possible in cancer treatment. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by OSTX to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 09, 2025 07:00 AM Eastern Daylight Time

Centre for Neuro Skills Named to Newsweek’s America's Greatest Midsize Workplaces 2025

Centre for Neuro Skills

Newsweek named Centre for Neuro Skills (CNS), a leading provider of post-acute brain injury and stroke rehabilitation services, one of America’s Greatest Midsize Workplaces for 2025. CNS is the only neurorehabilitation provider listed in the healthcare category, achieving a 5-star rating. “We are incredibly honored to receive this recognition from Newsweek,” said David Harrington, president and CEO of CNS. “At Centre for Neuro Skills, we believe a great workplace not only is built on trust, respect and a shared commitment to growth but also fosters an environment where every employee can thrive, contribute and feel valued. This recognition is a testament to the power of our collective team’s dedication, collaboration and passion.” To determine award recipients, Newsweek partnered with Plant-A Insights to analyze more than 3.5 million online employee reviews and public data for 9,000 companies employing 500-1,000 individuals. A third-party data provider, Aniline, then leveraged its database of more than 120 key performance indicators, including leadership, integrity, compensation, career development, culture and belonging and work-life balance, to gain a comprehensive view of workplace performance and satisfaction for U.S.-based companies. CNS, with seven locations across California and Texas, recently announced a new location – its fifth in Texas – opening in late 2025 in Plano. The new clinic at 1640 Dallas Parkway Suite 3000 will include the full set of CNS services, including programs for vision, neurobehavior, cognitive retraining, speech, physical and occupational therapy with certified, highly trained clinical therapy staff. It will also feature advanced care technology, such as the ZeroG® Gait and Balance System and a Bioness Integrated Therapy System to aid in vision, motor and balance training. Focused on patient-tailored care and maximizing patient outcomes, CNS offers residential inpatient, day treatment, telerehabilitation and continued care programs to help patients regain independence through community reintegration and life skills building. Learn more about CNS’ programs here. *** About Centre for Neuro Skills Centre for Neuro Skills is an experienced and respected world leader in providing intensive rehabilitation and medical programs for those recovering from all types of brain injury. Recognized as one of America's Greatest Midsize Workplaces 2025 by Newsweek, CNS covers a full spectrum of advanced care from residential and assisted living to outpatient/day treatment. Founded by Dr. Mark Ashley in 1980, CNS has seven locations in California and Texas. For moreinformation about Centre for Neuro Skills, visit neuroskills.com, Facebook, Twitter, LinkedIn, YouTube. For a video overview of CNS, visit our YouTube channel. Media, please note: To request an interview with CNS leadership or clinical staff, please contact Robin Carr at 415.766.0927 or CNS@landispr.com. ### Contact Details Robin Carr +1 415-766-0927 cns@landispr.com Company Website https://www.neuroskills.com/

April 02, 2025 08:01 AM Pacific Daylight Time

Image

Stem Cell Innovators: 4 Companies Advancing Regenerative Medicine

ADIA FATE MESO CRSP

Stem cells have a unique ability—they can transform into different types of cells, making them a game-changer in regenerative medicine. From repairing heart tissue after a heart attack to potentially reversing neurodegenerative diseases like Alzheimer's, the possibilities are vast. While their potential has been known for years, challenges such as immune rejection and difficulty in controlling cell differentiation have slowed progress. However, advances in DNA and RNA research have given scientists better control over the process, opening the door to real-world treatments. The stem cell industry is now shifting from theoretical breakthroughs to tangible medical applications. In 2024, the global stem cell market was valued at $15.1 billion and is projected to grow at an annual rate of 11.41% through 2030. This surge is driven by increased research, growing demand for stem cell banking, and major strides in precision medicine. Now, let's take a closer look at a few stocks making waves in this sector. ADIA Nutrition Inc. (OTC Pink: ADIA) is quickly becoming a company to watch in the stem cell and regenerative medicine space. The company operates through two main divisions: a nutritional supplement business and its medical division, Adia Med, which is focused on advanced stem cell therapies. ADIA’s recent announcements and strong growth trajectory suggest the company is positioning itself as a leader in this high-potential sector. One of the company's standout moves is its commitment to expanding stem cell treatments across the United States. In January 2025, ADIA opened its flagship clinic in Winter Park, Florida, where it already offers treatments using umbilical cord stem cells (UCB-SC) to address conditions like Multiple Sclerosis, orthopedic injuries, and joint pain. The clinic exceeded financial expectations in its first month, covering all startup costs and proving that there is strong demand for its therapies. This success set the stage for further growth, including the opening of satellite locations across the country. ADIA’s medical division, Adia Med, is also making waves with its decision to offer Therapeutic Plasma Exchange (TPE) at all future full-service clinic locations. TPE, which removes harmful substances from a patient's blood, is being used to treat a variety of conditions, including Alzheimer’s disease. This is a major move in a rapidly growing field. According to ADIA’s CEO, Larry Powalisz, “Our current location is already delivering this therapy, and as we grow, every new full clinic equipped with top-tier apheresis machines will expand access to this innovative care.” This technology sets ADIA apart from other players in the field and positions the company to lead in advanced treatment options for patients with neurodegenerative diseases. Another area where ADIA is taking a leadership role is in the standardization of stem cell treatments. The company is working on setting new quality and safety standards for umbilical cord stem cell use in the United States. With many clinics offering subpar or non-viable stem cells, ADIA is aiming to make sure every patient gets stem cells that are live and effective. As CEO Larry Powalisz stated, “We’re crafting a movement for reliability and excellence.” The company plans to present its standards to the FDA and the Department of Health and Human Services, pushing for nationwide regulations that could transform the entire stem cell industry. On top of that, ADIA is preparing to expand internationally, as multiple overseas organizations have expressed interest in licensing the company’s treatments. The company is already in the process of reviewing the legal and regulatory steps required to bring its innovative therapies, like its flagship Adia Vita stem cell product, to other markets. ADIA’s international expansion could help it tap into a global market for regenerative medicine, offering the company even more room to grow. Lastly, ADIA’s asset-light expansion model is another key factor driving its growth. In March 2025, the company opened its first satellite clinic in Tinton Falls, New Jersey, in partnership with Keep Glowing Medical Spa and Dr. Michael Ellis. This shared space partnership allows ADIA to expand quickly without the overhead costs of building new clinics from the ground up. The Tinton Falls location will offer ADIA’s stem cell therapies, including Adia Vita and AdiaLink, to patients seeking advanced treatments for a variety of conditions. ADIA Nutrition’s combination of strong financial performance, strategic partnerships, and commitment to innovative treatments makes it an exciting stock to watch in the stem cell space. With its focus on quality, expanding treatment options, and international growth, ADIA is positioning itself to be a leader in regenerative medicine. Investors looking for a company with significant growth potential in this booming sector should keep an eye on ADIA as it continues to expand and evolve. Fate Therapeutics (NASDAQ: FATE) is a clinical-stage biopharmaceutical company that is making strides in developing stem cell therapies for both cancer and autoimmune diseases. The company's approach is built around induced pluripotent stem cells (iPSCs), which can be used to create cell therapies that are ready to be used right off the shelf. This eliminates some of the challenges of traditional stem cell treatments, which require personalized, patient-specific cells. By creating universal, off-the-shelf therapies, Fate aims to make stem cell treatments more accessible and cost-effective. One of the most promising candidates in Fate’s pipeline is FT819, a type of CAR T-cell therapy designed to treat autoimmune diseases, particularly systemic lupus erythematosus (SLE). FT819 is especially notable because it doesn’t require the usual chemotherapy conditioning that other CAR T-cell therapies do. Early trials of FT819 have shown strong potential. The first three patients treated with FT819 experienced no dose-limiting toxicities, and one patient even went into remission after the treatment. Bob Valamehr, Fate’s President of Research and Development, expressed his excitement over the results, saying, “We are pleased with the early clinical data, which continues to support the potential for disease transformation.” In addition, the FDA has allowed Fate to expand its trials to include additional autoimmune diseases, which could broaden the market for FT819 significantly. Fate’s pipeline doesn’t stop with FT819. The company is also advancing other therapies, like FT825 and FT522, which target different types of cancers. FT825 is designed to treat solid tumors, while FT522 focuses on blood cancers. Like FT819, these therapies aim to simplify the treatment process by avoiding the need for chemotherapy conditioning. FT522, for example, uses natural killer (NK) cells to target B-cell cancers, offering a promising new way to treat patients with difficult-to-treat cancers. On the financial side, Fate Therapeutics is well-funded, with $307 million in cash and investments at the end of 2024. This gives the company plenty of resources to continue advancing its clinical programs, and the company’s strong partnerships with firms like Ono Pharmaceutical further enhance its growth potential. With its innovative approach to off-the-shelf stem cell therapies, Fate Therapeutics is positioning itself as a leader in the field. Its therapies for autoimmune diseases and cancer are showing real promise, and with strong financial backing, the company is poised for continued progress in the years ahead. Mesoblast Limited (NASDAQ: MESO) is a global leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe, life-threatening inflammatory diseases. The company's therapies leverage its proprietary mesenchymal stromal cell (MSC) technology, which works by releasing anti-inflammatory factors to help modulate the immune system and reduce harmful inflammation. This technology is aimed at addressing conditions like steroid-refractory acute graft-versus-host disease (SR-aGvHD) and chronic heart failure, among others. Mesoblast's FDA-approved product, Ryoncil (remestemcel-L), is the first MSC-based therapy to gain approval for the treatment of pediatric patients with SR-aGvHD, a life-threatening condition that occurs after bone marrow transplants. In December 2024, the U.S. FDA approved Ryoncil for use in children as young as two months old, marking a significant milestone for the company. The therapy has demonstrated strong clinical results, with a 70% overall response rate in a Phase 3 trial and a survival rate of 49% at four years for children treated with Ryoncil. The company is also working on expanding Ryoncil’s applications to other inflammatory diseases, such as adult SR-aGvHD and biologic-resistant inflammatory bowel disease (IBD). Furthermore, Mesoblast is advancing its second key product, Rexlemestrocel-L (Revascor), which is being studied for chronic heart failure and chronic low back pain. These treatments offer promising alternatives to existing therapies by addressing the underlying inflammation that often complicates these diseases. In terms of growth and financial stability, Mesoblast has been proactive in securing strategic partnerships and expanding its market presence. The company has agreements in key regions such as Japan, Europe, and China. Additionally, it has an extensive intellectual property portfolio, with over 1,000 granted patents covering MSC compositions, manufacturing methods, and therapeutic indications. Financially, Mesoblast is in a strong position, with a cash balance of $38 million at the end of 2024. The company raised an additional $161 million in a private placement, which bolsters its ability to continue advancing its research and development initiatives. Mesoblast’s CEO, Dr. Silviu Itescu, expressed his enthusiasm about the future, noting, "Our FDA-approved product Ryoncil will be available in the coming weeks to children with SR-aGvHD in need of life-saving therapy." Overall, Mesoblast’s strong pipeline of therapies and its leadership in the allogeneic cell medicine space position it as a promising company in the stem cell and regenerative medicine sectors. With its recent FDA approval and expanding commercial partnerships, Mesoblast is set to make a significant impact in treating inflammatory diseases globally. CRISPR Therapeutics (NASDAQ: CRSP) is a pioneer in gene editing, making history as the first company to bring a CRISPR-based therapy to market. The company’s flagship product, CASGEVY, was approved in multiple countries in late 2023 to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT)—two serious genetic blood disorders. Since then, patient demand has been strong, with over 50 authorized treatment centers (ATCs) worldwide and more than 50 patients having initiated cell collection by the end of 2024. Looking ahead, 2025 is shaping up to be a big year for CRISPR Therapeutics. The company is working on next-generation gene-editing programs and expanding into new disease areas like oncology, autoimmune disorders, and cardiovascular diseases. CEO Samarth Kulkarni called 2025 a "milestone-rich year" with major clinical updates expected across the company’s pipeline. While CASGEVY’s commercial rollout continues, CRISPR Therapeutics is making progress on several other fronts. CTX112 is a next-generation CAR T-cell therapy for blood cancers and autoimmune diseases. Early results showed strong efficacy in lymphoma patients, earning it a Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. In cardiovascular disease, CTX310 and CTX320 are experimental therapies targeting cholesterol and lipoprotein(a), a genetic risk factor for heart disease. Clinical updates are expected in the first half of 2025. CTX211 is a gene-edited stem cell therapy for Type 1 diabetes (T1D), designed to free patients from insulin injections without needing long-term immune suppression. CRISPR Therapeutics ended 2024 with $1.9 billion in cash and investments, giving it a strong financial cushion to fund research and commercialization efforts. The company has also partnered with Vertex Pharmaceuticals on CASGEVY, benefiting from Vertex’s commercial expertise as they roll out the therapy globally. Disclaimers: RazorPitch Inc. "RazorPitch" is not operated by a licensed broker, a dealer, or a registered investment adviser. This content is for informational purposes only and is not intended to be investment advice. The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions, or future events or performances are not statements of historical fact and may be forward-looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward-looking statements in this action may be identified through the use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or impaired due to the speculative nature of the companies profiled. RazorPitch has been retained and compensated by ADIA to assist in the production and distribution of this content. RazorPitch is responsible for the production and distribution of this content. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. This content is for informational purposes only; you should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained in this article constitutes a solicitation, recommendation, endorsement, or offer by RazorPitch or any third-party service provider to buy or sell any securities or other financial instruments. All content in this article is information of a general nature and does not address the circumstances of any particular individual or entity. Nothing in this article constitutes professional and/or financial advice, nor does any information in the article constitute a comprehensive or complete statement of the matters discussed or the law relating thereto. RazorPitch is not a fiduciary by virtue of any persons use of or access to this content. Contact Details RazorPitch Mark McKelvie +1 585-301-7700 mark@razorpitch.com Company Website http://razorpitch.com

April 02, 2025 07:00 AM Eastern Daylight Time

Mid-Sized Data Centers Are Winning the Communications Battle While Many Industry Leaders Fall Behind

Hot Paper Lantern

Hot Paper Lantern (HPL), an integrated communications and marketing agency that helps brands build their reputations, create meaningful impact, and generate growth, released its latest data center industry study, "Who's Owning the Conversation?" The study analyzed over 35 companies spanning three key verticals: data center operators, cooling technology vendors, and network service providers. Data Center Operators included in the study: Aligned Data Centers • CloudHQ • Cologix • Compass Datacenters • COPT • CoreSite • DataBank • Digital Core REIT • EdgeConneX • Evoque Data Center Solutions • Flexential • OVHcloud • QTS Data Centers • Sabey Data Centers • STACK Infrastructure • Switch Inc. • Tencent Cloud • Vantage Data Centers Cooling Technology Vendors included in the study: Amana Heating & Air • American Standard • Bryant Heating & Cooling • Goodman Manufacturing • Heil Heating & Cooling • Nortek Global • Rheem • Rudd Heating & Cooling • York Air Conditioning • York International Network Service Providers included in the study: Adtran • Allied Telesis • Calix • Cambium Networks • D-Link • Inseego • MikroTik • TP-Link • Viavi Solutions • Zyxel Communications The research examines how these companies are shaping the mid-market narrative, identifies key areas for improvement, and offers data-driven strategies to help companies drive meaningful engagement. While some organizations take a proactive approach to their external communications by leveraging social media and media relations, others remain passive and allow third parties to shape their company’s narrative. This contrast sparks critical questions about how key sectors engage with their stakeholders and whether or not they will fully capitalize on the opportunities presented by the data center industry's unprecedented growth. "Data center operators have assumed that by just being active to generate some form of media coverage alone, this will translate to having a strong reputation. Our research proves that this is not the case. If you are not actively shaping your own story, someone else will do it for you, and often not in your favor," said Ed Moed, chief executive officer at Hot Paper Lantern. "The data center industry has grown exponentially in recent years, fueled by massive investments, technological advancement, and industry demand. Many companies have relied on that growth to define their value in the market, but as competition increases, a strong and strategic narrative is what will set organizations apart." Key Insights from the Study: Public Perception Doesn't Always Align with Coverage Volume – More coverage does not always translate to a stronger reputation. Nearly 10% of all social media conversations about the data center industry are negative. However, over 80% of that negativity comes from just two companies, and both are among the most active on social media. Their outsized presence has amplified criticism, highlighting the risks of lacking a strategic online narrative. Mid-Tier Operators Punch Above Their Weight in Influence — Despite having smaller budgets, some mid-tier data centers generate outsized impact. Based on revenue, the bottom half of companies analyzed averaged 7x more coverage and 15x more engagement, demonstrating the power of strategic messaging. Cooling Technology Vendors Are Missing Their Storytelling Opportunity — With sustainability and energy efficiency becoming critical topics, cooling providers remain surprisingly underrepresented in industry conversations. Ninety percent of cooling brands generate fewer than 500 media mentions across major platforms, creating a massive opportunity for those willing to participate in the discussion. Network Providers Are Failing to Engage the Data Center Audience — Despite playing a crucial role in data center operations, many network providers struggle to connect with their target audience. Most rely on generic product announcements rather than crafting narratives that will resonate with data center decision-makers. As a result, the top 40% of network providers account for 95% of the industry's digital visibility, leaving the majority with little influence in the conversation. "Cooling and network providers have expanded alongside the data center industry, yet their voice in industry discussions has not kept pace," said Moed. "As artificial intelligence accelerates demand for advanced infrastructure, these sectors must step forward. The companies that fail to establish themselves as industry leaders risk being overlooked, while those that actively shape the conversation will define the next phase of innovation and growth." For more details on the "Who's Owning the Conversation?" study, view the report here. HPL will continue tracking industry trends and key players, releasing quarterly reports about the evolving conversation. To stay informed on the latest findings and updates, visit www.hotpaperlantern.com and sign up for future reports. Hot Paper Lantern (HPL) is a New York City-based integrated communications and marketing agency that helps brands build their reputations, create meaningful impact, and generate growth. HPL partners with clients to find, engage, and form deeper connections with key audiences and stakeholders. For more information, visit www.hotpaperlantern.com. Contact Details Hot Paper Lantern emoed@hotpaperlantern.com Company Website https://hotpaperlantern.com/

April 01, 2025 10:00 AM Eastern Daylight Time

UNOS adds two members to its board of directors

United Network for Organ Sharing

Today, the United Network for Organ Sharing (UNOS) announced that its Board of Directors has unanimously approved two new board members, bringing the board complement to nine. Melina Davis and Mark Johnson will begin their terms on April 1, 2025, serving until September 30, 2028. They were approved by a full board vote on March 24. “I’m pleased to welcome Melina and Mark to the UNOS Board of Directors,” said Sue Dunn, chair of the UNOS board of directors. “They each have an incredible background that exemplifies UNOS’ strategic priorities and work to help save and improve lives.” Davis and Johnson bring decades of executive leadership to the UNOS Board of Directors, both within and outside of healthcare. Davis is the CEO and executive vice president of the Medical Society of Viriginia and Johnson is the former CEO of Averhealth and BetterMed Urgent Care. “I’m honored to join the UNOS Board of Directors. UNOS is an organization that’s committed to enhancing the lives and health of individuals. Together, with my fellow board members, I will advocate for innovative solutions, enhance donor awareness, and strive to improve the overall donation and transplant system,” said Davis. “By collaborating, we can advance our goal to give hope and a second chance to many individuals and their families. I look forward to engaging with the community and harnessing our collective expertise to drive meaningful change.” “It’s an honor to be appointed to the UNOS Board of Directors, and for the opportunity to work with UNOS’ CEO Maureen McBride and the UNOS team as they pursue strategic initiatives to provide critical, high-value organ sharing and transplant services,” said Johnson. “As the complex organ transplantation system undergoes change, UNOS’ breadth and depth of know-how, and its extensive relationships with transplant hospitals and other stakeholders, point to a bright future for UNOS and for the many patients who rely on critical organ donations. I look forward to contributing strategic, financial and capital deployment support to UNOS as it advances its mission.” Davis and Johnson join UNOS’ current seven-member board, whose term began on March 30, 2024: Sue Dunn, former CEO of Donor Alliance Bapu Jena, M.D., Ph.D., professor of health care policy at Harvard Medical School, internist at Massachusetts General Hospital Maryl Johnson, M.D., professor at the University of Wisconsin School of Medicine Irene Kim, M.D., director of the Comprehensive Transplant Center at Cedars-Sinai Jake Kouns, founder of RVAsec James Pittman, assistant vice president of transplant and dialysis services for HCA Healthcare Marie Quintero-Johnson, retired vice president of corporate development for Coca-Cola and kidney recipient About UNOS The United Network for Organ Sharing (UNOS) is a nonprofit organization that serves the organ donation and transplant system and broader public health community through its work developing new technologies and initiatives, conducting data-driven research and analysis, providing expert consulting services, advocating for patients, and being a leader in bringing communities together to save lives. Contact Details United Network for Organ Sharing Anne Paschke anne.paschke@unos.org Company Website https://unos.org

March 31, 2025 02:01 PM Eastern Daylight Time

Market Alert: Palatin's Disruptive Obesity Drug Combination Shows Groundbreaking Weight Loss Results in Phase 2 Topline Data (NYSE: PTN)

Global Markets News

Palatin Technologies* has unveiled compelling topline results from its Phase 2 study showing that patients receiving its obesity drug bremelanotide in combination with tirzepatide achieved a 4.4% weight reduction compared to just 1.6% for placebo—a highly statistically significant difference (p<0.0001). The eight-week trial demonstrated that combining these two mechanisms creates a synergistic effect, with 40% of patients in the combination group achieving at least 5% weight loss compared to 27% with tirzepatide alone. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Perhaps most intriguing for the obesity treatment landscape, Palatin's data revealed that its drug effectively halted the rapid weight regain typically seen after stopping GLP-1/GIP therapy. This addresses one of the most significant challenges facing current obesity treatments, where patients often regain substantial weight after discontinuation. The economic potential of anti-obesity drugs is enormous, with the market expected to reach US$100 billion by 2030. As obesity rates continue to climb globally, with the number of obese individuals worldwide projected to increase from 980 million to nearly 2 billion from 2022 to 2035, innovative treatment approaches like Palatin's are positioning themselves in this rapidly expanding market. Palatin is advancing development of next-generation long-acting injectable and oral versions of its obesity compounds, with investigational new drug applications planned for late 2025 and clinical data expected in early 2026. The company is one of just two developing therapies targeting this specific biological pathway for obesity. This announcement follows recent positive news from Palatin's ulcerative colitis program and FDA orphan drug designation for its oral obesity compound for rare genetic obesity disorders, demonstrating the company's momentum across multiple therapeutic areas with significant unmet needs. Subscribe For More Alerts: https://newsletter.page/wallstreetalerts Recent Palatin Technologies News Highlights: Palatin Announces Positive Topline Results from Phase 2 Ulcerative Colitis (UC) Study of Oral Melanocortin-1 Receptor Agonist PL8177 Completion of Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide Palatin Announces Positive Phase IIb BREAKOUT Study Results in Patients with Type 2 Diabetic Nephropathy Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis *DISCLAIMER: This alert is published by Wall Street Wire. Wall Street Wire does not provide financial or investment advice, and our content does not represent an offer to buy or sell securities. Wall Street Wire is a promotional content brand and its operators are not registered brokers, dealers, or investment advisers. This alert contains and is a form of paid promotional content for to Palatin Technologies and was produced as part of their paid subscription to Wall Street Wire’s distribution and promotional content services. This alert has not been reviewed or approved by Palatin Technologies prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms Contact Details Wall Street Wire Market Aerts Desk media.globalmarkets@gmail.com

March 31, 2025 09:19 AM Eastern Daylight Time

Coolidge Reagan Foundation Files Congressional Ethics, FEC, and DOJ Criminal Complaints Against Rep. Jasmine Crockett

Coolidge Reagan Foundation

The Coolidge Reagan Foundation (CRF), a First Amendment watchdog, has filed a series of complaints against Representative Jasmine Crockett (D-TX), alleging serious ethical and legal violations, including voter intimidation, fraudulent campaign contributions, and misconduct in office. The complaints, simultaneously submitted to the Federal Election Commission (FEC), the Office of Congressional Ethics (OCE), and the Department of Justice (DOJ), expose Rep. Crockett’s alleged illegal activities and efforts to undermine fair elections and democratic processes. “Rep. Crockett’s reckless rhetoric and open encouragement of political violence are not only unacceptable but dangerously irresponsible, stated Shaun McCutcheon, Chairman of the Coolidge Reagan Foundation. “While I am an advocate for Free Speech, the fact is no Member of Congress should be inciting attacks on American voters. You can’t call on your supporters to attack people any more than you can yell fire in a crowded theater. Her actions must be condemned and investigated.” “This is a blatant abuse of power and a direct assault on free and fair elections,” Dan Backer, Counsel to CRF added. “From voter intimidation to potentially fraudulent campaign financing, Rep. Crockett’s conduct raises serious legal and ethical concerns. The American people deserve accountability, and Crockett must answer for her unethical, potentially criminal, and just plain dirty acts.” The complaint filed with the Department of Justice highlights Rep. Crockett’s alarming rhetoric and online activity, which appear to violate the Federal Voting Rights Act prohibiting voter intimidation. On March 9, 2025, Crockett circulated an animated video through social media depicting a cartoon version of herself and Rep. Alexandria Ocasio-Cortez brutally attacking a Republican voter. This video, broadcast to hundreds of thousands of her followers, not only condones but seemingly encourages political violence against Republicans. Her public statements, including referring to "full-on combat," further demonstrate a pattern of incitement that places American voters at risk. CRF is calling on the DOJ to investigate these actions under 52 U.S.C. § 10307(b) and other applicable federal statutes. CRF's complaint to the FEC details an apparent scheme in which Rep. Crockett’s campaign committee, ‘Jasmine for US’, accepted and falsely reported contributions processed through ActBlue. The filing reveals that an elderly retiree, Mr. Randy Best of Plano, Texas, was listed as making over 2,500 contributions totaling more than $21,000 – including more than 50 to Crockett (transactions that Mr. Best’s wife denies ever occurred). The sheer volume and pattern of these donations suggest an elaborate money-laundering scheme orchestrated through ActBlue to funnel illegal contributions to Democratic candidates, including Rep. Crockett. CRF demands an immediate FEC investigation into these violations of 52 U.S.C. § 30122, which prohibits accepting contributions in the name of, or with the funds of, another. In addition to potential criminal and campaign finance violations, CRF has also filed a complaint with the Office of Congressional Ethics, asserting that Rep. Crockett has engaged in behavior that fails to reflect creditably on the U.S. House of Representatives. Her public threats against Republican officials, Tesla CEO Elon Musk, and former President Donald Trump (paired with the incendiary video) constitute a clear violation of House Rule XXIII, which mandates ethical conduct by Members. Furthermore, her acceptance of potentially fraudulent contributions through ActBlue raises serious concerns about her fitness for office and adherence to congressional financial disclosure requirements. Shaun McCutcheon further emphasized the seriousness of the complaints stating “Congresswoman Crockett’s actions are a disgrace to the office she holds. Inciting violence against political opponents and engaging in fraudulent campaign finance practices are violations that cannot be ignored. CRF will not stand idly by while elected officials break the law and erode trust in our institutions.” Dan Backer added “We have seen a disturbing trend where ActBlue is used as a willing conduit for a potentially 8 or 9 figure sum of illegal campaign money laundering, and Rep. Crockett’s campaign is just one example. The FEC must investigate this apparent scheme to launder funds in the names of unsuspecting donors. Additionally, her rhetoric and public statements demand a full review by the DOJ for potential voter intimidation violations.” CRF calls for swift action to hold Rep. Crockett accountable and protect the integrity of our democratic process. The news of these complaints was first reported by Fred Lucas in the Daily Signal. ### Please visit: https://www.coolidgereagan.org/ For more information or to schedule an interview with a CRF spokesperson, contact Dan Rene at 202-329-8357 or dan@danrene.com Contact Details Coolidge Reagan Foundation Dan Rene +1 202-329-8357 dan@danrene.com Company Website https://www.coolidgereagan.org/

March 28, 2025 09:00 AM Eastern Daylight Time

Ekshef.com Celebrates Three Years of Revolutionizing Healthcare Accessibility in Egypt

Rev Up Marketers

Ekshef.com, Egypt's top online doctor appointment booking website, celebrates its third anniversary with pride and reaffirms its commitment to making healthcare accessible and convenient for patients nationwide. Since its launch in 2022, the platform has successfully bridged the gap between medical professionals and patients, providing free, convenient appointment booking services. Founded by Khaled Khamis, a developer of science and software engineering and a visionary entrepreneur, Ekshef.com has grown exponentially over the past three years. Having graduated from the Faculty of Science (Chemistry & Microbiology) in 2004, Khamis transitioned into software engineering by 2008. His technical and healthcare background has propelled the success of Ekshef, and it has turned out to be a game-changer in Egypt's healthcare industry. Today, Ekshef.com boasts a network of over 11,000 certified physicians in Egypt's major capital cities such as Cairo, Giza, and Alexandria. By making it easier to search for doctors and easily book appointments, Ekshef.com enabled thousands of patients to easily take control of their healthcare needs with ease. “At Ekshef.com, we believe in leveraging technology to remove barriers in healthcare accessibility,” said Ekshef.com Founder and CEO Khaled Khamis. "Completing our third anniversary is an achievement, and we are committed to expanding our platform and optimizing the patient experience." According to Crunchbase, Ekshef.com has obtained a total of $250,000 in funds from unidentified angel investors. Funds have been significant in enhancing platform features, streamlining user experience, and increasing presence across Egypt's healthcare ecosystem. Through its solid tech foundation, Ekshef.com is able to empower patients to seek and book visits with specialists across all medical specializations, ranging from cardiology and dermatology to pediatrics and more. The website is designed to accommodate the evolving needs of patients, offering them an easy and quick way of reaching high-quality medical professionals. Patients seeking specialist consultation can search through a comprehensive database of doctors in Cairo and other major cities. This brings healthcare to all, more than ever before. Ekshef.com's user-friendly interface, doctor listings verified by professionals, and real-time appointment booking facility have made it a leading name in digital healthcare services. The quick growth of the company is a testament to the growing need for effective, technology-based solutions in Egypt's healthcare industry. As Ekshef.com enters its fourth year of activities, the company is eagerly awaiting the next wave of expansion and technical growth. The team continues to work hard to add more features, bring in newer offerings, and cover more unserved areas to give every patient access to high-quality healthcare with minimal waiting times. Our goal is to continue innovating with the needs of the patients and physicians," Khamis said. “We are dedicated to making healthcare more accessible, reliable, and seamless for every Egyptian.” About Ekshef.com Ekshef.com is Egypt’s fastest-growing doctor booking platform, revolutionizing healthcare access by connecting patients with trusted medical professionals across the country. Founded in 2022 by Khaled Khamis, Ekshef.com has rapidly expanded its network to over 11,000 doctors in major cities like Cairo, Giza, and Alexandria, making it easier than ever to find and book appointments with qualified specialists. To learn more and book an appointment, visit Ekshef.com. Contact Details Ekshef for information technology Khaled Khamis contact@ekshef.com Company Website https://ekshef.com/

March 27, 2025 02:57 PM Eastern Daylight Time

Image